Catalent Inc (CTLT)

[Trend-Setter]

New Mymetics Data Regarding Cold Chain Independent Virosome Based Vaccines to be Presented at AAPS in Washington, D.C.

-Poster presentation showing retention of structural integrity and good immunogenicity of spray dried virosome-based vaccine stored at different temperatures and administered as a nasal powder

-Poster presentation at AAPS - Washington, D.C., USA, Tuesday November 6th, 2018

The poster with the title "Developing Cold Chain Independent Vaccines - Spray-drying of Virosomes to Produce Dry Powder Formulations" will be presented by Dr. Richard Johnson, the CEO of Upperton Ltd, on Tuesday the 6th of November. Dr. Johnson will discuss that the successful spray drying of the Mymetics' HIV virosome-based candidate vaccine. The spray dried powder formulation stored at 4°C (40°F) or 40°C (104°F) maintained its structural integrity, while the liquid formulation showed strong structural degradation at 40°C (104°F). Further, a pre-clinical in vivo study confirmed that the nasal delivery of spray dried virosomes was an effective, needle-free route for immunization, with levels of immune response comparative to that obtained by subcutaneous injection.

Upperton Pharma Solutions Ltd., based in Nottingham, the United Kingdom, has a long track record in overcoming complex spray drying formulation challenges in the pharmaceutical industry and has an R&D and pilot plant facility for the manufacturing from small scale to clinical batches of spray dried drug substances and products.

The MACIVIVA project will end early November 2018 and may receive up to €5.3 million funding from the European Union's Horizon 2020 research and innovation program under Grant Agreement No 646122.

https://finance.yahoo.com/news/mymetics-data-regarding-cold-chain-133500521.html